Features | Partner Sites | Information | LinkXpress
Sign In

Blood Test Detects Patients at Risk for Diabetes

By Christina Chang, LabMedica Regional Director
Posted on 17 Jul 2012
AACC 2012: A new test being showcased can stratify patients based on risk for developing diabetes.

Even within the healthy range of hemoglobin A1C, the test, dubbed Quantose, detects patients' risk of developing diabetes. It is a novel blood test for prediabetes that reflects insulin resistance. The test is based on three recently identified nonglycemic biomarkers and insulin, and detects progression to prediabetes earlier than traditional glycemic measures such a hemoglobin A1C.

Metabolon (Research Triangle Park, NC, USA) is showcasing the Quantose test, which is a metablomics-driven diagnostic, at the American Association for Clinical Chemistry Lab Expo (AACC) being held from July 15-19, 2012, in Los Angeles (CA, USA). Two posters highlighting the clinical utility of Quantose are being presented at the Expo.

In a poster, the clinical utility of Quantose as a simple, practical measure of insulin resistance will be demonstrated in this poster session with data highlighting the correlations between Quantose and other known risk factors for type 2 diabetes and cardiovascular disease.

In a second poster, differences in insulin resistance using HbA1c and metabolic markers Alpha-hydroxybutyrate, Linoleoyl-GPC, and Oleate are described. This clinical study was performed at the University of North Carolina (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance. Data include the finding that Quantose scores closely track worsening dysglycemia as defined by hemoglobin A1C, but that Quantose also identifies a substantial subset of patients as insulin resistant despite hemoglobin A1C values within the normal range (<5.7%). The clinical study was performed at the University of North Carolina, (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance.

Metabolon, Inc. has developed technology to quickly identify and measure all biochemicals in a biological sample. This method provides a precise understanding of disease etiology and drug action, and advances personalized medicine.

Related Links:

Metabolon
University of North Carolina




comments powered by Disqus

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Genetic Tests

view channel
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).

Promising Blood Biomarkers Isolated for Colorectal Cancer

The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.